StageSeries D | Alive
Last Raised$24.7M | 14 yrs ago
About Chroma Therapeutics
Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.
Missing: Chroma Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Chroma Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Chroma Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Chroma Therapeutics is included in 2 Expert Collections, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Chroma Therapeutics Patents
Chroma Therapeutics has filed 5 patents.
Clusters of differentiation, Cytokines, Monoclonal antibodies, Inflammations, Autoimmune diseases
Clusters of differentiation, Cytokines, Monoclonal antibodies, Inflammations, Autoimmune diseases
Latest Chroma Therapeutics News
Feb 16, 2021
| 2027 Industry Value Touches US$ 28,606.6 Million in Terms of Revenue | by CellCentric Ltd., Celleron Therapeutics Ltd., Celgene Corporation, Chroma Therapeutics Ltd. etc Impact Analysis of Covid-19 The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters. Epigenetic therapy is the use of drugs or other epigenome-influencing techniques to treat medical conditions such as cancer, heart disease, diabetes, and mental illnesses. At present, a few drugs targeting epigenetic enzymes as well as analogues of epigenetic modifications have been introduced into the clinic use. Statistics: The global epigenetic drugs and diagnostic technologies market is estimated to account for US$ 28,606.6 Mn in terms of 2027. Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-sample/4026 Global Epigenetic Drugs and Diagnostic Technologies Market: Drivers Approval and launch of epigenetic drugs is expected to propel growth of the global epigenetic drugs and diagnostic technologies market over the forecast period. For instance, in January 2020, the U.S. Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.) for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Global Epigenetic Drugs and Diagnostic Technologies Market: Opportunities Adoption of Artificial Intelligence (AI) for R&D in epigenetic drugs is expected to offer lucrative growth opportunities for players in the global epigenetic drugs and diagnostic technologies market. Epigenetic drug targets are particularly suited for AI studies. The use of AI in pre-clinical drug discovery offers the potential to reduce the cycle time for lead identification. Tailored Information as per niche requirement: LIMITED TIME OFFER – Hurry Up! Get Discount For Buyers UPTO 30% OFF On Any Research Report Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000 Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/4026 Global Epigenetic Drugs and Diagnostic Technologies Market: Restraints Unique reactions of each patient to drugs leads to various challenges for the scientists and researchers studying genomic alterations and their phenotypic expression, which is expected to hinder growth of the market. Key Takeaways: The global epigenetic drugs and diagnostic technologies market was valued at US$ 6,800.3 Mn in 2019 and is forecast to reach a value of US$ 28,606.6 Mn by 2027 at a CAGR of 19.7% between 2020 and 2027. Increasing approval and launch of epigenetic drugs is expected to propel growth of the global epigenetic drugs and diagnostic technologies market over the forecast period. Epigenetic Drugs segment held dominant position in the global epigenetic drugs and diagnostic technologies market in 2019, accounting for 71.5% share in terms of value, increasing prevalence of cancer is expected to propel growth of the segment during the forecasted period. Market Trends Players in the market are focused on R&D of new drugs to expand their product portfolio. For instance, in July 2020, Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics for R&D of novel therapies, presented the final data from its Phase IIa clinical trial REIMAGINE at the 28th European Congress of Psychiatry, EPA 2020. Major players in the market are also focused on raising funds for R&D of new technologies. For instance, in June 2020, Base Genomics, an epigenetics company, raised US$ 11 million to progress development of its TAPS technology, a novel chemical reaction that converts methylated cytosine to thymine under mild conditions. Global Epigenetic Drugs and Diagnostic Technologies Market: Competitive Landscape Major players operating in the global epigenetic drugs and diagnostic technologies market include 4SC AG, Acetylon Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., CellCentric Ltd., Celleron Therapeutics Ltd., Celgene Corporation, Chroma Therapeutics Ltd., Epigentek Group Inc., Eisai Co. Ltd., EnVivo Pharmaceuticals Inc., Base Genomics, and Oryzon Genomics, S.A. View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/epigenetics-drugs-and-diagnostic-technologies-market-3296 Global Epigenetic Drugs and Diagnostic Technologies Market: Key Developments June 2020: Epizyme, Inc. received the U.S. Food and Drug Administration’s supplemental New Drug Application approval for TAZVERIK (tazemetostat) for the following two distinct follicular lymphoma indications. March 2018: EpiGentek announced its technological and financial support for new skincare startup EpigenCare for development and commercialization of a personalized skincare test based on epigenetic markers. Segmentation Epigenetic Drugs
Chroma Therapeutics Frequently Asked Questions (FAQ)
What is Chroma Therapeutics's latest funding round?
Chroma Therapeutics's latest funding round is Series D.
How much did Chroma Therapeutics raise?
Chroma Therapeutics raised a total of $103.3M.
Who are the investors of Chroma Therapeutics?
Investors of Chroma Therapeutics include Abingworth, Wellcome Trust, Gilde Healthcare, EW Healthcare Partners, Phase4 Ventures and 3 more.
Who are Chroma Therapeutics's competitors?
Competitors of Chroma Therapeutics include Affibody, Elusys Therapeutics, MaxCyte, Trellis Bioscience, LeadScope, Array Biopharma, NGM Biopharmaceuticals, Threshold Pharmaceuticals, Zymeworks, ARIAD Pharmaceuticals and 18 more.
Compare Chroma Therapeutics to Competitors
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).
Dialectica offers Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases. The mission of Dialectica is to add value to the link between research and pharmaceutical and biotechnology companies that are active in the discovery of therapeutics for brain diseases. Dialectica develops and optimize Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases.
Pique Therapeutics is a biotechnology company focused initially on the treatment of cancer. Pique's lead product is a therapeutic vaccine for non-small cell lung cancer in Phase 2 clinical trials. Pique is also utilizing its therapeutic vaccine technology in additional areas of oncology, with products in pre-clinical stage for pancreatic, colorectal, and head and neck cancers.
Arcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's core technology is based on research which showed that in many neuropathic pain conditions, the signal that triggers pain actually arises at the level of the skin. This finding provides a strong biological rationale for developing topically delivered drugs to target the pain at the source - the pain receptors in the skin. Arcion's product pipeline comprises multiple candidates to treat neuropathic pain. ARC-4558 is a topical 0.1% clonidine gel being developed for the treatment of painful diabetic neuropathy (PDN). It is a clear, water-based, fast-drying gel that provides pain relief that rivals approved oral drugs. ARC-4558 has a minimal side-effect profile with low/undetectable systemic levels of clonidine with over 600 patients treated in clinical trials to date.
Limerick BioPharma is developing compounds that per the company when used adjunctively with both marketed and investigational drugs improve drug side effect profiles and clinical outcomes. By activating cellular transport pumps to redistribute drugs away from organs and tissues where they have adverse effects, the company's compounds aim to minimize toxic side effects at non-targeted vulnerable organs and tissues while maintaining or enhancing a drug's desired effects. Per the company, Limerick's pipeline molecules are applicable to a broad range of therapeutic drug classes including immunosuppressants, opioids, immunomodulators, selective estrogens receptor modulators, and psychotropics. In the monotherapy setting, Limerick is developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia via a mechanism related to reverse cholesterol transport.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.